Affordable Access

deepdyve-link
Publisher Website

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.

Authors
  • Yang, James Chih-Hsin1
  • Cheng, Ying2
  • Murakami, Haruyasu3
  • Yang, Pan-Chyr4
  • He, Jianxing5
  • Nakagawa, Kazuhiko6
  • Kang, Jin Hyoung7
  • Kim, Joo-Hang8
  • Hozak, Rebecca R9
  • Nguyen, Tuan Stevon9
  • Zhang, Wan Li10
  • Enatsu, Sotaro11
  • Puri, Tarun12
  • Orlando, Mauro13
  • 1 National Taiwan University Hospital, Taipei, Taiwan. Electronic address: [email protected] , (Taiwan)
  • 2 Jilin Provincial Cancer Hospital, Changchun, China. , (China)
  • 3 Shizuoka Cancer Center, Shizuoka, Japan. , (Japan)
  • 4 National Taiwan University Hospital, Taipei, Taiwan. , (Taiwan)
  • 5 The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China. , (China)
  • 6 Kindai University Faculty of Medicine, Osaka, Japan. , (Japan)
  • 7 The Catholic University of Korea, Seoul, Korea. , (North Korea)
  • 8 CHA Bundang Medical Center, CHA University, Gyeonggi-do, Korea. , (North Korea)
  • 9 Eli Lilly and Company, Indianapolis, Indiana. , (India)
  • 10 Eli Lilly China, Shanghai, China. , (China)
  • 11 Eli Lilly Japan K.K., Kobe, Japan. , (Japan)
  • 12 Eli Lilly and Company, Gurgaon, Haryana, India. , (India)
  • 13 Instituto Alexander Fleming, Buenos Aires, Argentina. , (Argentina)
Type
Published Article
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publication Date
Jan 01, 2020
Volume
15
Issue
1
Pages
91–100
Identifiers
DOI: 10.1016/j.jtho.2019.09.008
PMID: 31605797
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Clinical studies have shown that a combination of a tyrosine kinase inhibitor (TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor (EGFR) TKI in NSCLC. Previously, pemetrexed+gefintib (P+G) had improved progression-free survival (PFS) compared with gefitinib. We present OS, updated PFS, biomarker analysis, and safety of P+G versus gefitinib. This was a phase 2, multicenter, randomized study conducted in East Asian patients with advanced nonsquamous NSCLC with EGFR mutations. Patients were randomized (2:1) to receive P+G (500 mg/m2 intravenously 3-weekly + 250 mg/day orally) or gefitinib. In total, 191 patients (P+G, n=126; gefitinib, n=65) comprised the intent-to-treat and safety populations. Median OS was 43.4 months in P+G versus 36.8 months in gefitinib arm; adjusted HR 0.77 (95% CI, 0.5-1.2); one-sided P=0.105. Median PFS was significantly longer in the P+G (16.2 months) versus gefitinib arm (11.1 months); adjusted HR 0.67 (95% CI, 0.5-0.9); one-sided P=0.009. In the P+G and gefitinib arms, median PFS was 22.6 and 11.0 months, respectively, in patients with low thymidylate synthase (TS) expression, and 12.6 and 9.9 months, respectively, in patients with high TS expression. Common second-line post-discontinuation systemic therapies were EGFR-TKIs and chemotherapy. Most patients experienced at least one adverse event. Addition of pemetrexed to EGFR TKI gefitinib resulted in significantly improved PFS and numerically longer OS compared with gefitinib in treatment-naïve patients with EGFR-mutated advanced nonsquamous NSCLC. Low TS expression appeared to be a good predictor for treatment outcomes. Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times